Individualized dosing strategies in breast cancer chemotherapy: Evidence for therapeutic drug monitoring-guided docetaxel treatment
TDM-guided docetaxel dosing significantly reduced ADRs and improved cost efficiency in breast cancer chemotherapy. These findings support the implementation of TDM as a superior strategy to traditional BSA-based dosing, with potential to enhance both patient safety and healthcare resource utilization.
Authors
- Shengying Qin (ORCID: https://orcid.org/0000-0002-8458-5960)
- Ruizhuo Ouyang (ORCID: https://orcid.org/0000-0003-0562-7569)
- Yong-Zhe Tang
- Jin Zhang (ORCID: https://orcid.org/0000-0001-7241-0760)
- Xiaoqing Zhang (ORCID: https://orcid.org/0000-0002-3652-723X)
- Yamin Liu (ORCID: https://orcid.org/0000-0003-0031-7799)
- Junwei Fan (ORCID: https://orcid.org/0000-0001-8214-2974)
- Wei Huang (ORCID: https://orcid.org/0000-0001-8047-3286)
- Hai Zhang
- Haiou Yang
Institutions
- University of Shanghai for Science and Technology (CN)
- Shanghai Jiao Tong University (CN)
- International Peace Maternity & Child Health Hospital (CN)
- Shanghai First People's Hospital (CN)
- Shanghai First Maternity and Infant Hospital (CN)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2025-12-10
- DOI
- https://doi.org/10.1016/j.ejps.2025.107407
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00